Royalty Pharma acquires royalties on Lexiscan
Royalty Pharma has acquired the rights to certain royalties payable on sales of the pharmacologic stress agent Lexiscan and the antibiotic Cubicin from an undisclosed seller for a cash payment of $487 million.
Lexiscan (regadenoson) is a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Lexiscan was co-developed by CV Therapeutics (now Gilead) and Astellas, said the New York City-based Royalty Pharma.
Cubicin (daptomycin for injection) is a bacteriocidal, IV antibiotic with activity against MRSA, or methicillin-resistant staphylococcus aureus, added the company.
Lexiscan (regadenoson) is a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Lexiscan was co-developed by CV Therapeutics (now Gilead) and Astellas, said the New York City-based Royalty Pharma.
Cubicin (daptomycin for injection) is a bacteriocidal, IV antibiotic with activity against MRSA, or methicillin-resistant staphylococcus aureus, added the company.